



DOCKET NO.: UBC-0003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Paul Keown et al.

Serial No.: 10/070,796

Filing Date: December 16, 2002

For: **DIAGNOSTIC AND THERAPEUTIC METHODS IN AUTOIMMUNE DISEASE**

Confirmation No.: 7651

Group Art Unit: Unknown

Examiner: Unknown

DATE OF DEPOSIT: March 3, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, DC 20231.

TYPED NAME: Jeffrey J. Kang
REGISTRATION NO.: 38,515

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

GP/ 1645

RECEIVED
MAR 10 2003
TECH CENTER 1600/2800

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

English language abstracts have been included for those listed references which are not in the English language.

Date: March 3, 2003


Jeffrey M. King
Registration No. 38,515

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **6**

Complete if Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

RECEIVED
MAR 10 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	US-5,972,604		10-26-1999	SANTAMARIA <i>et al.</i>	
	2	US-5,965,787		10-12-1999	LUTHRA <i>et al.</i>	
	3	US-5,698,195		12-16-1997	LE <i>et al.</i>	
	4	US-5,645,994		07-08-1997	HUANG	
	5	US-5,627,264		05-06-1997	FODOR <i>et al.</i>	
	6	US-5,399,346		03-21-1995	ANDERSON <i>et al.</i>	
	7	US-5,166,320		11-24-1992	WU and WU	
	8	US-4,980,286		12-25-1990	MORGAN and MULLIGAN	
	9	US-4,868,116		09-19-1989	MORGAN and MULLIGAN	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	10	WO	97/38310	10-16-1997	SUCIU-FOCA		<input type="checkbox"/>
	11	WO	96/40989	12-19-1996	ALLIBERT <i>et al.</i>		<input type="checkbox"/>
	12	WO	95/05452	02-23-1995	BAETGE <i>et al.</i>		<input type="checkbox"/>
	13	WO (GB)	95/29235 (2288807)	11-02-1995	BELL <i>et al.</i>		<input type="checkbox"/>
	14	WO	92/07573	05-14-1992	RAFIELD <i>et al.</i>		<input type="checkbox"/>
	15	WO	89/07136	08-10-1989	WILSON and MULLIGAN		<input type="checkbox"/>
	16	WO	89/05345	06-15-1989	WILSON and MULLIGAN		<input type="checkbox"/>
	17	WO	89/02468	03-23-1989	MULLIGAN and WILSON		<input type="checkbox"/>
	18	EPO	0 896 999	02-17-1999	TOYOSAKI-MAEDA <i>et al.</i>		<input type="checkbox"/>

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
Unsaved Document



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **6**

Complete if Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	ACSADI et al. (1991) Nature 352:815-818.	
	20	ANDERSON (2000) Science 288:627-9.	
	21	ARMENTANO et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145.	
	22	AUSUBEL FM. et al. (eds.) "Current Protocols in Molecular Biology" Greene Publishing Associates, Sections 9.10-9.14.	
	23	AWATA T. et al. (1994) Diabetologia 37:1159-1162.	
	24	BOEHM U. et al. (1997) Annu Rev Immunol 15:749-95.	
	25	BOHME U. et al. (1985) J. Immunol. 135:2149-2155.	
	26	BERKNER et al. (1988) BioTechniques 6:616.	
	27	CAVAZZANA-CALVO et al. (2000) Science 288:669-72.	
	28	CERNA M. et al. (1995) Arch. Immunol. Ther. Exp. (Wasz) 43(2):139-144.	
	29	CHOWDHURY et al. (1991) Science 254:1802-1805.	
	30	CLAPP DW. et al.(1991) Blood 78: 1132-1139.	
	31	COMBE et al. (1995) Br. J. Rheumatol. 34: 529-534.	
	32	CRISTIANO et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126.	
	33	CURIEL el al. (1991) Proc. Natl. Acad. Sci. USA 88:8850-8854.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

RECEIVED
MAR 10 2003
TECH CENTER 1600/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	DAI et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895.	
	35	DANOS and MULLIGAN (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464.	
	36	DUPONT B. (1989) Hum. Immunol. 26:3-14.	
	37	EGLITIS et al. (1985) Science 230:1395-1398.	
	38	FARRAR MA. and SCHREIBER RD. (1993) Annu Rev Immunol. 11:571-611.	
	39	FELDMANN M. et al. (1996) Annu Rev Immunol. 14:397-440.	
	40	FELDMANN M. et al. (1996) Cell 85(3):307-10.	
	41	FERRY et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381.	
	42	FLOTTE et al. (1993) J. Biol. Chem. 268:3781-3790.	
	43	FLOTTE et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356.	
	44	GILES and CAPRA (1985) Adv. Immunol. 37:1-71.	
	45	GREGERSON et al. (1987) Arthritis Rheum 30:1205-1213.	
	46	HERMONAT et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470.	
	47	HERZ and GERARD (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816.	
	48	HUBER et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

RECEIVED
MAR 10 2003
TECH CENTER 1600/2000

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	49	HUTCHINSON et al. (1999) <i>Transplant Proc.</i> , 31(1-2): 734-736.	
/	50	HWU et al. (1993) <i>J. Immunol.</i> 150:4104-4115.	
/	51	JACOB CO. et al. (1993) <i>Immunogenetics</i> 38:251-257.	
/	52	JOHN S. et al. (1998) <i>Ann. Rheum. Dis.</i> 57:361-365.	
/	53	JOHN S. et al. (1998) <i>Cytokine</i> 10(6):466-470.	
/	54	JOHN S. et al. (1997) <i>Am. J. Hum. Gen.</i> 61(4)suppl. abstract 2341.	
/	55	KAY et al. (1992) <i>Human Gene Therapy</i> 3:641-647.	
/	56	KHANI-HANJANI et al. (1998) Abstract 293, Poster Session B, American College of Rheumatology 62nd National Meeting.	
/	57	KHANI-HANJANI et al. (2000) <i>Lancet</i> 356:820-825.	
/	58	LANG B. et al. (1990) <i>Zeitschrift fur Rheumatologie</i> 49(4):197-207. (abstract only - German article)	
/	59	LEMARCHAND et al. (1992) <i>Proc. Natl. Acad. Sci. USA</i> 89:6482-6486.	
/	60	MACHOLD et al. (1992) <i>Ann. Rheum. Dis.</i> 51(9):1039-43.	
/	61	McLAUGHLIN et al. (1989) <i>J. Virol.</i> 62:1963-1973.	
/	62	MILLER AD. (1990) <i>Blood</i> 76(2):271-278.	
/	63	MOLKENTIN J. et al. (1993) <i>Annals Rheum. Dis.</i> 52:610-612.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete If Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

RECEIVED
MAR 10 2003
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	64	MUZYCZKA et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129.	
	65	NEPOM et al. (1996) <i>J.Rheumatol.</i> 23 (suppl 44): 5-9.	
	66	QUANTIN et al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584.	
	67	REVEILLE (1998) <i>Curr. Op. Rheumatol.</i> 10: 187-200.	
	68	ROSENFELD et al. (1991) Science 252:431-434.	
	69	ROSENFELD et al. (1992) Cell 68:143-155.	
	70	RUIZ-LINARES A, (1993) Hum Mol Genet 2(9):1508.	
	71	SAMULSKI et al. (1989) J. Virol. 63:3822-3828.	
	72	SCHIFF (1997) <i>Am. J. Med.</i> 102 (suppl 1A): 11S-15S.	
	73	TRATSCHIN et al. (1985) Mol. Cell. Biol. 5:3251-3260.	
	74	TRATSCHIN et al. (1984) Mol. Cell. Biol. 4:2072-2081.	
	75	TRATSCHIN et al. (1984) J. Virol. 51:611-619.	
	76	TROWSDALE et al. (1985) Immunol. Rev. 85:5-43.	
	77	van BEUSECHEM et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644.	
	78	van der HORST-BRUINSMA et al. (1999) Human Immunology 60:152-158.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
Unsaved Document



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	10/070,796
Filing Date	December 16, 2002
First Named Inventor	KEOWN, Paul
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	UBC-0003

RECEIVED
MAR 10 2003
TECH CENTER 160012900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	79	WEYAND and GORONZY (1997) J. Mol. Med. 75:772-785.	
	80	WEYAND and GORONZY (1995) Curr. Op. Rheumatol. 7: 206-213.	
	81	WILLIAMS et al. (1993) DNA and Cell Biology 12(5):425-434.	
	82	WILSON et al. (1992) J. Biol. Chem. 267:963-967.	
	83	WILSON et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018.	
	84	WOLFF et al. (1990) Science 247:1465-1468.	
	85	WONDISFORD et al. (1988) Mol. Endocrinol. 2:32-39.	
	86	WU G. and WU CH. (1988) J. Biol. Chem. 263:14621-14624.	
	87	WUCHERPFENNIG et al. (1995) Proc. Natl. Acad. Sci. 92:11935-11939.	
	88	ZANELLI et al. (1998) Immunogenetics 48:394-401.	
	89	ZANELLI et al. (1998) Abstract 174, Poster Session A, American College of Rheumatology 62nd National Meeting.	
	90	ZANELLI et al. (1997) J. Immunol 158:3545-3551.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document